The cardiomyopathies market is set to grow from $1.6 billion in 2021 to $5.2 billion in 2031 across the seven major markets (7MM*) at a compound annual growth rate (CAGR) of 12.4%, according to GlobalData. The leading data and analytics company notes that growth in the US, 5EU*, and Japan will largely be driven by late-stage pipeline products.

According to GlobalData’s report, ‘Cardiomyopathies Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021-2031’, cardiomyopathies are most often managed with generic drugs such as beta blockers, angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs).

Sarah Bundra, Pharmaceutical Analyst at GlobalData, comments: “Although these drugs have been mainstays in cardiomyopathy management for decades, they are also used for many other indications such as chronic kidney disease (CKD) and coronary artery disease (CAD), and, as such, are non-specific in nature and do not address the underlying pathophysiology of cardiomyopathy.”

Two late-stage pipeline products, Camzyos (mavacamten) and aficamten, will launch across the 7MM during the forecast period, driving growth globally and providing therapeutics for obstructive hypertrophic cardiomyopathy (HCM). The label expansion of Entresto (sacubitril + valsartan) to cardiomyopathies during the forecast period will also be an important factor for sales growth.

Bundra continues: “Obstructive HCM has yet to be the target of clinical trial development, so Camzyos and aficamten are bringing therapeutics to a previously neglected patient population. However, these drugs are novel not only in their target indication, but also in their mechanism of action as myosin inhibitors. Thus, these drugs will be very successful and contribute heavily to growth in the cardiomyopathies market.”

Of the 7MM, the US will contribute the most to cardiomyopathy sales revenue, accounting for 94.2% of sales in 2021 and 96.4% in 2031. This is due to the greater prevalence of dilated cardiomyopathy (DCM) in the US, higher price of pharmaceuticals, and earlier launch of key pipeline products.

*7MM: The US, 5EU (France, Germany, Italy, Spain, and the UK), and Japan